Abstract
Pharmacokinetic studies were conducted with human immunodeficiency virus-infected patients receiving efavirenz, nelfinavir, or both agents at weeks 4 and 32. Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone. There were no significant differences in efavirenz pharmacokinetics.
| Original language | English |
|---|---|
| Pages (from-to) | 3558-3561 |
| Number of pages | 4 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 49 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 1 2005 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
Cite this
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naïve, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. / Smith, Patrick F.; Robbins, Gregory K.; Shafer, Robert W.; Wu, Hulin; Yu, Song; Hirsch, Martin S.; Merigan, Thomas C.; Park, Jeong Gun; Forrest, Alan; Fischl, Margaret A; Morse, Gene D.
In: Antimicrobial Agents and Chemotherapy, Vol. 49, No. 8, 01.08.2005, p. 3558-3561.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naïve, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors
AU - Smith, Patrick F.
AU - Robbins, Gregory K.
AU - Shafer, Robert W.
AU - Wu, Hulin
AU - Yu, Song
AU - Hirsch, Martin S.
AU - Merigan, Thomas C.
AU - Park, Jeong Gun
AU - Forrest, Alan
AU - Fischl, Margaret A
AU - Morse, Gene D.
PY - 2005/8/1
Y1 - 2005/8/1
N2 - Pharmacokinetic studies were conducted with human immunodeficiency virus-infected patients receiving efavirenz, nelfinavir, or both agents at weeks 4 and 32. Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone. There were no significant differences in efavirenz pharmacokinetics.
AB - Pharmacokinetic studies were conducted with human immunodeficiency virus-infected patients receiving efavirenz, nelfinavir, or both agents at weeks 4 and 32. Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone. There were no significant differences in efavirenz pharmacokinetics.
UR - http://www.scopus.com/inward/record.url?scp=23044447776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23044447776&partnerID=8YFLogxK
U2 - 10.1128/AAC.49.8.3558-3561.2005
DO - 10.1128/AAC.49.8.3558-3561.2005
M3 - Article
C2 - 16048984
AN - SCOPUS:23044447776
VL - 49
SP - 3558
EP - 3561
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 8
ER -